MARKET

ANAB

ANAB

Anaptysbio Inc
NASDAQ
50.10
+0.09
+0.18%
Closed 16:47 12/26 EST
OPEN
50.00
PREV CLOSE
50.01
HIGH
50.18
LOW
49.50
VOLUME
197.91K
TURNOVER
0
52 WEEK HIGH
51.43
52 WEEK LOW
12.21
MARKET CAP
1.39B
P/E (TTM)
-17.7748
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ANAB last week (1222-1226)?
Weekly Report · 2h ago
Top AnaptysBio Insider Makes Major Move With Fresh Stock Sale
TipRanks · 5d ago
AnaptysBio Director J. Anthony Ware Reports Sale of Common Shares
Reuters · 5d ago
AnaptysBio Chief Medical Officer Paul F. Lizzul Reports Disposal of Common Shares
Reuters · 5d ago
AnaptysBio CFO Dennis Mulroy Reports Sale of Common Shares
Reuters · 5d ago
AnaptysBio Chief Legal Officer Eric J. Loumeau Reports Sale of Common Shares
Reuters · 5d ago
Weekly Report: what happened at ANAB last week (1215-1219)?
Weekly Report · 12/22 10:02
AnaptysBio (ANAB): Assessing an 8x Price-to-Sales Valuation After a Strong Share Price Run-Up
Simply Wall St · 12/20 13:13
More
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

Webull offers AnaptysBio Inc stock information, including NASDAQ: ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.